Literature DB >> 15856155

[Intra-arterial thrombolysis of the middle cerebral artery: an overview].

T Struffert1, S Ruffing, W Reith.   

Abstract

Until 1996, treatment of strokes consisted exclusively of efforts to prevent recurrence. The development of intravenous and intra-arterial thrombolysis changed the approach to a causal therapy. This article provides an overview of state-of-the-art intravenous and intra-arterial therapeutic concepts and attempts to define the position of the local intra-arterial fibrinolysis approach.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856155     DOI: 10.1007/s00117-005-1205-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke.

Authors:  Rejane C Lisboa; Borko D Jovanovic; Mark J Alberts
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

2.  Local intraarterial fibrinolysis in the carotid territory.

Authors:  J Theron; P Courtheoux; A Casasco; F Alachkar; F Notari; F Ganem; D Maiza
Journal:  AJNR Am J Neuroradiol       Date:  1989 Jul-Aug       Impact factor: 3.825

Review 3.  Thrombolytic stroke therapy: past, present, and future.

Authors:  J A Zivin
Journal:  Neurology       Date:  1999-07-13       Impact factor: 9.910

4.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

5.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Authors:  Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Does arterial recanalization improve outcome in carotid territory stroke?

Authors:  R von Kummer; R Holle; L Rosin; M Forsting; W Hacke
Journal:  Stroke       Date:  1995-04       Impact factor: 7.914

8.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.